98%
921
2 minutes
20
Cold-inducible RNA-binding protein (CIRP) is a stress-response protein that has been shown to protect cardiomyocytes under a variety of stress conditions from apoptosis. Our recent study showed that the expression of CIRP protein in the heart was downregulated in patients with heart failure and an animal model of ischaemia heart failure, but its role in heart failure is still unknown. The present study aimed at evaluating the potential role of CIRP on the heart in an animal model of myocardial infarction (MI). MI model of rats was induced by the ligation of the left coronary artery. CIRP overexpression was mediated by direct intracardiac injection of adeno-associated virus serotype 9 (AAV9) vectors carrying a CIRP coding sequence with a cardiac-specific promoter before the induction of the MI model. The effects of CIRP elevation on MI-induced heart were analysed through echocardiographic, pathological and molecular analysis. Our results showed that the intracardiac injection of AAV9 successfully mediated CIRP upregulation in cardiomyocytes. Upregulation of cardiac CIRP prevented MI-induced cardiac dysfunction and adverse remodelling, coupled with the reduced inflammatory response in the heart. Collectively, these results demonstrated the beneficial role of intracellular CIRP on the heart and suggest that CIRP may be a therapeutic target in ischaemic heart disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472646 | PMC |
http://dx.doi.org/10.1111/jcmm.70084 | DOI Listing |
JCI Insight
September 2025
Department of Pharmacology, University of Michigan, Ann Arbor, United States of America.
Cardiac hypertrophy is a common adaptation to cardiovascular stress and often a prelude to heart failure. We examined how S-palmitoylation of the small GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1), impacts cardiomyocyte stress signaling. Mutation of the cysteine-178 palmitoylation site impaired activation of Rac1 when overexpressed in cardiomyocytes.
View Article and Find Full Text PDFApoptosis
September 2025
The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, 182 Chunhui Road, Longmatan District, Luzhou, 646000, China.
Diabetic cardiomyopathy (DCM) is a severe cardiovascular complication of diabetes mellitus, characterized by pathological changes such as cardiomyocyte hypertrophy, necrosis, and myocardial fibrosis, which can ultimately lead to heart failure. However, its underlying mechanisms remain incompletely understood, limiting the development of effective therapeutic approaches. In recent years, the critical roles of oxidative stress and ferroptosis in the pathogenesis of DCM have attracted increasing attention.
View Article and Find Full Text PDFCardiovasc Interv Ther
September 2025
Division of Cardiovascular Medicine, Toyohashi Heart Center, Aichi, Japan.
The outcome of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) is still controversial for patients with left main coronary artery (LMCA) disease. This multicenter cohort study aimed to evaluate the clinical outcomes of LMCA disease patients who underwent PCI or CABG. We reviewed 875 consecutive patients diagnosed with LMCA disease between January 2009 and December 2020 who underwent coronary revascularization by PCI (n = 404) or CABG (n = 471).
View Article and Find Full Text PDFJ Interv Card Electrophysiol
September 2025
Federal University of Minas Gerais, R. Alfredo Balena, 190, Santa Efigênia, Belo Horizonte, Brazil.
Background: Chagas heart disease (ChD) is a significant public health concern in Latin America, contributing to a high incidence of sudden cardiac death (SCD). Despite advances in heart failure treatment, management of Chagas cardiomyopathy has not progressed accordingly. While ICDs are effective for primary and secondary prevention in other conditions, patients with ChD often experience more frequent episodes of ventricular tachycardia, and ICD use may provide a negative impact and increase mortality.
View Article and Find Full Text PDFCurr Cardiol Rep
September 2025
Division of Cardiology, Health Sciences Building, University of Washington Medical Center, 1959 NE Pacific StreetSuite #A506D Box 356422, Seattle, WA, 98195, USA.
Purpose Of Review: Patients living with cancer are at risk for significant potential cardiovascular complications as a direct result of cancer treatment or due to underlying comorbid cardiovascular disease. This article reviews the methods of risk stratification as well as pharmacologic and nonpharmacologic approaches to cardioprotection in cardio-oncology.
Recent Findings: Several cancer-specific risk stratification tools have incorporated variables such as age, sex, cancer subtype, traditional cardiovascular risk factors and cancer treatment-related parameters to assess cardiovascular specific risk prior to cancer therapy.